{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:45:27Z","timestamp":1794584727667,"version":"4.9.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The causes and circumstances surrounding death are poorly studied in patients with portopulmonary hypertension (PoPH). We sought to determine the specific reasons for dying and characteristics surrounding this process in patients with PoPH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>All deaths of patients with PoPH followed in the Cleveland Clinic Pulmonary Vascular Program were prospectively reviewed by the pulmonary hypertension team between 1996 and 2020.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>A total of 69 patients with PoPH (age 56.0\u2009\u00b1\u20098.9 y), with 49% females, were included. Causes of death were available in 52 (75%) patients, of these PoPH either directly or indirectly contributed to death in 13 of 52 (25%) of patients, meanwhile 39 of 52 (75%) of the patients died because of progressive liver disease and its related complications. Decompensated liver disease was the leading cause of death in this cohort 20 of 52 (38%), whereas 19 of 52 (37%) died because of conditions associated with liver disease. About half, 36 of 69 (52%) of patients died in a healthcare environment and 23 of 36 (64%) during a hospitalization at Cleveland Clinic. A total of 59 of 69 (74%) of patients received pulmonary arterial hypertension (PAH)-specific therapies. Six patients died after liver transplantation (in 3 death was related to PAH-related complications). Most of the patients in this cohort of PoPH patients were considered unsuitable for liver transplantation for a variety of reasons. Advanced healthcare directives were available in only 28% of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Most patients with PoPH died because of complications of their liver disease. PAH directly or indirectly contributed to death in a third of them. A quarter of them did not receive PAH-specific therapy before their death.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001162","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T18:00:39Z","timestamp":1623261639000},"page":"e710","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Causes and Circumstances of Death in Portopulmonary Hypertension"],"prefix":"10.1097","volume":"7","author":[{"given":"Sandeep","family":"Sahay","sequence":"first","affiliation":[{"name":"Weill Cornell Medical College, Institute of Academic Medicine, Houston Methodist Lung Center, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Al Abdi","sequence":"additional","affiliation":[{"name":"Inflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Melillo","sequence":"additional","affiliation":[{"name":"Inflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Newman","sequence":"additional","affiliation":[{"name":"Inflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed A.","family":"Dweik","sequence":"additional","affiliation":[{"name":"Inflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH."},{"name":"Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A.","family":"Heresi","sequence":"additional","affiliation":[{"name":"Inflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH."},{"name":"Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano R.","family":"Tonelli","sequence":"additional","affiliation":[{"name":"Inflammation and Immunity Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH."},{"name":"Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"R1-20240805","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1164\/rccm.201209-1640OC","article-title":"Causes and circumstances of death in pulmonary arterial hypertension.","volume":"188","author":"Tonelli","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R2-20240805","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0735-1097(87)80123-7","article-title":"Coexistent pulmonary and portal hypertension: morphologic and clinical features.","volume":"10","author":"Edwards","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"R3-20240805","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/jhep.2003.50060","article-title":"Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study.","volume":"37","author":"Colle","year":"2003","journal-title":"Hepatology"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/lt.20459","article-title":"Hemodynamics and survival of patients with portopulmonary hypertension.","volume":"11","author":"Kawut","year":"2005","journal-title":"Liver Transpl"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep.21431","article-title":"Portopulmonary hypertension: results from a 10-year screening algorithm.","volume":"44","author":"Krowka","year":"2006","journal-title":"Hepatology"},{"key":"R6-20240805","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jlts.2000.6356","article-title":"Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation.","volume":"6","author":"Krowka","year":"2000","journal-title":"Liver Transpl"},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the study of liver diseases and the American Society of transplantation.","volume":"59","author":"Martin","year":"2014","journal-title":"Hepatology"},{"key":"R8-20240805","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/TP.0000000000001666","article-title":"Predictors of waitlist mortality in portopulmonary hypertension.","volume":"101","author":"DuBrock","year":"2017","journal-title":"Transplantation"},{"key":"R9-20240805","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1378\/chest.11-0160","article-title":"Portopulmonary hypertension: a report from the US-based REVEAL registry.","volume":"141","author":"Krowka","year":"2012","journal-title":"Chest"},{"key":"R10-20240805","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/lt.23870","article-title":"Long-term follow-up of portopulmonary hypertension patients after liver transplantation.","volume":"20","author":"Khaderi","year":"2014","journal-title":"Liver Transpl"},{"key":"R11-20240805","article-title":"Clinical outcomes after liver transplantation in patients with portopulmonary hypertension.","author":"Cartin-Ceba","year":"2020","journal-title":"Transplantation"},{"key":"R12-20240805","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.28990","article-title":"Long-term outcome in liver transplantation candidates with portopulmonary hypertension.","volume":"65","author":"Savale","year":"2017","journal-title":"Hepatology"},{"issue":"25 Suppl","key":"R13-20240805","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension.","volume":"62","author":"Hoeper","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R14-20240805","doi-asserted-by":"crossref","first-page":"569413","DOI":"10.3389\/fmed.2020.569413","article-title":"Portopulmonary hypertension: from bench to bedside.","volume":"7","author":"Thomas","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R15-20240805","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.30197","article-title":"Treatment barriers in portopulmonary hypertension.","volume":"69","author":"AbuHalimeh","year":"2019","journal-title":"Hepatology"},{"key":"R16-20240805","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1097\/TXD.0000000000001085","article-title":"Outcomes of liver transplantation in treated portopulmonary hypertension patients with a mean pulmonary arterial pressure \u226535 mm\u2009Hg.","volume":"6","author":"DuBrock","year":"2020","journal-title":"Transplant Direct"},{"key":"R17-20240805","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jhep.2020.02.021","article-title":"Portopulmonary hypertension in the current era of pulmonary hypertension management.","volume":"73","author":"Savale","year":"2020","journal-title":"J Hepatol"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/lt.21365","article-title":"Treatment of portopulmonary hypertension\u2013isn\u2019t it time to move forward?","volume":"14","author":"Swanson","year":"2008","journal-title":"Liver Transpl"},{"key":"R19-20240805","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"R20-20240805","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R22-20240805","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1164\/ajrccm.165.3.200109-0130c","article-title":"Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.","volume":"165","author":"Hoeper","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R23-20240805","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1164\/rccm.200804-613OC","article-title":"Portopulmonary hypertension: survival and prognostic factors.","volume":"178","author":"Le Pavec","year":"2008","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:09:25Z","timestamp":1722834565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001162","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]}}}